Loading
companiesCompany
Regeneron
Regeneron makes Libtayo and has a large portfolio of CD3 bispecifics (odronextamab, linvoseltamab).
Overview
Regeneron, based in Tarrytown, New York, and listed as REGN, makes Libtayo, or cemiplimab, and has a large portfolio of CD3 bispecific antibodies including odronextamab and linvoseltamab. Odronextamab targets CD20 by CD3 in lymphoma, linvoseltamab, a BCMA by CD3 bispecific, was approved in 2025 for myeloma, fianlimab is a LAG-3 antibody in a phase 3 with cemiplimab in first-line melanoma, and costimulatory bispecifics follow. OnCo links it to cutaneous squamous cell carcinoma, basal cell carcinoma and cervical cancer through the EMPOWER-Cervical 1 trial, to lymphoma pages, to MUC16 as a target and to Arsenal Biosciences. Whether costimulatory bispecifics can make T-cell engagers work in solid tumours is the open question its pipeline is built to answer. Cemiplimab has its own page.
Headquarters
Tarrytown, NY, US
Scorecard
All companies#26of 1244 companies, score 95
- approved products +24
- phase 3 +3
- phase 1/2 +2
- targets +14
- modalities +8
- regions +6
- 24-month regulatory events +8
- registry trials +30
4 approved, 1 in phase 3, 2 earlier, 7 targets, 532 registry studies. Formula on the scorecards page.
Type
Large pharma · REGN
Stage
Public
Website
ApprovedMonoclonal antibody (anti-PD-1)
Cemiplimab · Libtayo
A PD-1 blocker that is the standard for advanced skin squamous cell carcinoma, and in 2025 became the first adjuvant immunotherapy for it.
Phase 3Monoclonal antibody (anti-LAG-3)
Fianlimab is Regeneron's LAG-3 blocking antibody, paired with the PD-1 blocker cemiplimab. A 60% phase 1 response rate in untreated melanoma prompted phase 3 trials, but the metastatic trial against pembrolizumab missed its progression endpoint in 2026.
ApprovedBispecific T-cell engager (BCMA×CD3)
Linvoseltamab · Lynozyfic
Linvoseltamab is Regeneron's BCMA bispecific, approved in July 2025 with the highest complete-response rate of the class in its pivotal study.
ApprovedBispecific T-cell engager (CD20×CD3)
Odronextamab · Lynozyfic (EU: Ordspono)
Odronextamab is Regeneron's CD20 bispecific, approved in Europe for lymphoma and in the US for follicular lymphoma after earlier FDA rejections over confirmatory-trial enrolment.
Phase 2Bispecific antibody
REGN7075 is a bispecific antibody from Regeneron Pharmaceuticals, in registered phase 2 trials for non-small-cell lung cancer, small-cell lung cancer.
Phase 2Bispecific T-cell engager (MUC16×CD3)
Ubamatamab (REGN4018) is Regeneron's investigational MUC16×CD3 bispecific antibody, in phase 1/2 and phase 2 trials for ovarian and endometrial cancer.
ApprovedRecombinant fusion protein (VEGF ligand trap)
Ziv-aflibercept · Zaltrap
Ziv-aflibercept (Zaltrap) is a decoy receptor that soaks up the blood-vessel growth signal VEGF. It is added to the FOLFIRI chemotherapy combination for bowel cancer that has spread and progressed after oxaliplatin.
Similar pages
- TechnologyT-cell engagers (bispecific)
Shares A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnose, A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H, A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve, A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Mult.
- CompanySanofi
Shares EMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9, Ziv-aflibercept, Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma, Cemiplimab in basal cell carcinoma after a hedgehog inhibitor.
- CancerAdvanced cutaneous squamous cell carcinoma
Shares Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma, Cemiplimab for kidney transplant recipients with advanced skin squamous cell carcinoma, Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinoma, C-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma).
- CancerSmouldering multiple myeloma
Shares A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With H, A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Deve, A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM), Linvoseltamab.
- TargetCD3
Shares Ubamatamab, A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat, Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma, Linvoseltamab.
cancers
fronts
targets
drugs
ApprovedMonoclonal antibody (anti-PD-1)
Cemiplimab · Libtayo
Phase 3Monoclonal antibody (anti-LAG-3)
ApprovedBispecific T-cell engager (BCMA×CD3)
Linvoseltamab · Lynozyfic
ApprovedBispecific T-cell engager (CD20×CD3)
Odronextamab · Lynozyfic (EU: Ordspono)
Phase 2Bispecific antibody
Phase 2Bispecific T-cell engager (MUC16×CD3)
ApprovedRecombinant fusion protein (VEGF ligand trap)
Ziv-aflibercept · Zaltrap
companies
trials
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not ReA First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who HavA Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With ColorectalA Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With HA Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of DeveA Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small CeA Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously TreatA Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory MultA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult PaA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or UbamataA Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-SmallA Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersA Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult ParticipantA Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate CancerA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With MetastaA Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With ReA Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 MelanomaA Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With ChemoA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and ChemothA Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back AfA Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple MyelomaA Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently DiagnoseAdaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE TrialAdding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum ChemothC-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal CancerCemiplimab for kidney transplant recipients with advanced skin squamous cell carcinomaCemiplimab in basal cell carcinoma after a hedgehog inhibitorCemiplimab With Fianlimab for Resectable Non-Metastatic Colon CancerCemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal CancerEMPOWER-Cervical 1 / GOG-3016 / ENGOT-cx9EMPOWER-CSCC-1EMPOWER-Lung 1Fianlimab + cemiplimab phase 3 (first-line melanoma)Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerLINKER-MM1Neoadjuvant cemiplimab for resectable stage II to IV skin squamous cell carcinomaNeoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsNeoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Featuresand 8 more →